Mark McPartland
@markmcp
Business development, corporate communications and capital markets advisory consultant. Early to rise - quick to listen - slow to speak - slower to anger!
You might like
“The completion of the PALISADE-3 Phase 3 public speaking challenge study marks an important milestone for Vistagen,” said Shawn Singh, President and Chief Executive Officer. businesswire.com/news/home/2025…
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder - businesswire.com/news/home/2025…
The Business of Mental Health with Shawn Singh via @justmoneynews moneynewsnetwork.com/podcast/trade-…
moneynewsnetwork.com
Money News Network | #1 Business and Finance Podcasts
15 award-winning shows reaching 5M+ monthly listeners. Founded by Nicole Lapin. Webby Award Winner.
Our CEO spoke with @PharmaVoice on the unique potential of our novel pherine nasal spray, fasedienol, for #socialanxiety disorder and the ongoing PALISADE-3 Ph 3 Study. Read more on fasedienol's potential to be the first on-demand treatment for SAD bit.ly/4aZ0aQk $VTGN
Existing #anxiety and #depression medications leave many people without a treatment that works—or a treatment that works with side effects that don’t. Our investigational nasal sprays, with potentially fewer side effects, have the potential to change that. bit.ly/3Vyp8Pk
6,000 people a day enter #menopause in the U.S. but six in every 10 women are left untreated. We are developing PH80 to improve the treatment paradigm for #HotFlashes & reduce the physical burden on quality of life experienced by women worldwide. $VTGN bit.ly/44cc5qI
Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug pink.pharmaintelligence.informa.com/articles/2023/…
America’s mental health crisis: Why we need a Moonshot pharmaphorum.com/rd/americas-me…
Vistagen reports favorable results from trial of MDD therapy clinicaltrialsarena.com/news/vistagen-… via @TrialsArena
clinicaltrialsarena.com
Vistagen reports favourable results from trial of MDD therapy
Vistagen has reported favourable results from a Phase I trial of itruvone (PH10) nasal spray for the treatment of major depressive disorder.
Revolutionizing Mental Health Treatment: VistaGen Therapeutics' Nasal Sp... youtu.be/j7dI8vSiCcw via @YouTube
youtube.com
YouTube
Revolutionizing mental health treatment: Vistagen Therapeutics' nasal...
CEO Shawn Singh spoke to @molecule2markt’s @ramanelli about the #MentalHealth epidemic and the potential of our pipeline medications to transform the treatment landscape for people living with CNS disorders. bit.ly/3CiWOYU #InnovatingMentalHealth
As Vistagen strives to develop transformative medicines for patients suffering from anxiety, depression and other mental health disorders, we prioritize supporting our employees’ mental health and well-being, both inside and outside of our workplace. businesswire.com/news/home/2023…
Great daily calendar to kick off Mental Health Month!
Looking for creative ways to stay engaged throughout #MentalHealthMonth? 🗓 Check out our printable calendar filled with ideas to make the world around you work for your #mentalhealth—just one of many resources you can find at mhanational.org/may.
It’s officially #MentalHealthMonth! We invite you to #LookAroundLookWithin as we shine a light on how our surroundings can impact #mentalhealth. 🧠 There are so many ways to raise awareness and get involved. Learn more: mhanational.org/may
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference - businesswire.com/news/home/2023…
businesswire.com
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, dep...
Tomorrow at 12:50 PM ET, Vistagen CEO Shawn Singh will give a presentation during the @TDCowen Health Care Conference. For details, visit: bit.ly/3mcArzr $VTGN #CowenHealthCare
A great episode of Talking Biotech with Dr. Kevin Folta and Shawn Singh @Vistagen discusses Treating Mental Illness through Nasal Drug Delivery - Listen along here: share.transistor.fm/s/2c5503ee/tra…
share.transistor.fm
Treating Mental Illness through Nasal Drug Delivery - Shawn Singh |...
“The initiation of this U.S. Phase 1 study of Vistagen’s novel pherine nasal spray, PH10, represents a major milestone for our team as well as for the millions of individuals left struggling with major depressive disorder." businesswire.com/news/home/2023…
United States Trends
- 1. #alert N/A
- 2. Ford N/A
- 3. #DeepNodeAI N/A
- 4. #signal N/A
- 5. Lakers N/A
- 6. TJ Sabula N/A
- 7. #FallonTonight N/A
- 8. #LakeShow N/A
- 9. Wemby N/A
- 10. Anton N/A
- 11. Peyton Watson N/A
- 12. Kansas N/A
- 13. Jalen Johnson N/A
- 14. Chet N/A
- 15. Iowa State N/A
- 16. Jrue Holiday N/A
- 17. Rock Chalk N/A
- 18. Dale Partridge N/A
- 19. Seton Hall N/A
- 20. Kai Cenat N/A
Something went wrong.
Something went wrong.